Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
News and press releases about Insmed Incorporated (INSM) provide insight into the company’s progress as a global biopharmaceutical organization focused on serious and rare diseases. Insmed regularly issues updates on its commercial performance, clinical trial milestones, regulatory decisions, and corporate initiatives across its respiratory, immunology & inflammation, and neuro & other rare disease programs.
Recent news has highlighted key events such as U.S. Food and Drug Administration approval of BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis, European Commission approval of BRINSUPRI for specified NCFB patients in the European Union, and detailed business updates around the commercial launch of BRINSUPRI and continued global growth of ARIKAYCE (amikacin liposome inhalation suspension). Investors can also follow announcements on the advancement of TPIP (treprostinil palmitil inhalation powder) into Phase 3 studies for pulmonary hypertension associated with interstitial lung disease and other pulmonary indications.
Insmed’s news flow also covers clinical data readouts from studies such as ASPEN and WILLOW in NCFB, the BiRCh and CEDAR trials evaluating brensocatib in additional neutrophil-mediated diseases, and early-stage developments in gene therapy programs INS1201, INS1202, and INS1203. Corporate communications include financial results, conference presentations at major healthcare and respiratory congresses, and updates on acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory conditions.
For followers of INSM stock, this news page offers a centralized view of Insmed’s ongoing commercial execution, regulatory interactions, and pipeline evolution. Regular updates help track how the company’s therapies and investigational candidates are progressing through development and reaching patient populations worldwide.
Insmed (Nasdaq: INSM) reported strong Q2 2025 financial results, with ARIKAYCE revenue reaching $107.4 million, up 19% year-over-year. The company maintained its 2025 ARIKAYCE revenue guidance of $405-425 million.
Key developments include: pending FDA approval for brensocatib in bronchiectasis (PDUFA date: August 12, 2025), positive Phase 2b results for TPIP in PAH, and Phase 3 studies planned for PH-ILD and PAH. The company reported a Q2 net loss of $321.7 million ($1.70 per share) and holds a strong cash position of $1.9 billion following a successful public offering that raised $823.1 million.
Insmed (Nasdaq: INSM) has scheduled its second-quarter 2025 financial results conference call for Thursday, August 7, 2025, at 8:00 a.m. ET. The company will release its financial results the same day.
Investors can join the conference call by dialing (888) 210-2654 (U.S.) or (646) 960-0278 (international) using access code 7862189. A live webcast will be available on Insmed's website. The call replay will be accessible until August 14, 2025, and the webcast recording will be archived for 90 days on the company's investor relations website.
Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company, has announced its participation in the 2025 Goldman Sachs Annual Global Healthcare Conference. The company's management will deliver a presentation on Wednesday, June 11, 2025, at 9:20 a.m. ET in Miami. Investors and interested parties can access the live webcast through Insmed's investor relations website section at www.insmed.com. The webcast recording will remain available for 30 days after the event concludes.
Insmed (Nasdaq: INSM), a global biopharmaceutical company focused on developing first- and best-in-class therapies for serious diseases, has announced its upcoming presentation at the BofA Securities 2025 Health Care Conference.
The presentation is scheduled for Tuesday, May 13, 2025, at 2:20 p.m. PT in Las Vegas. Interested parties can access the live webcast through the investor relations section of Insmed's website at www.insmed.com.
Key Details:
- Event: BofA Securities 2025 Health Care Conference
- Location: Las Vegas
- Date & Time: May 13, 2025, 2:20 p.m. PT
- Webcast Duration: Archive available for 30 days post-event
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
